MCLA-122

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameMCLA-122

Drug Alias NameAnti-HER-3/EGFR mAbs (Merus)Human Bispecific IgG mAbs (Merus)Anti-HER-3/EGFR mAbs (Merus)MCLA-122

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsReceptor tyrosine-protein kinase erbB-3 antagonists

TargetsEpidermal growth factor receptor erbB1Receptor tyrosine-protein kinase erbB-3

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlands

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesMerus Nv

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMerus Nv

Active IndicationsN/A

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A